Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002735231 | SCV003003058 | uncertain significance | not provided | 2022-01-28 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 2211 of the CDH23 protein (p.Ile2211Val). This variant is present in population databases (rs371363040, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with CDH23-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002710759 | SCV003577827 | uncertain significance | Inborn genetic diseases | 2021-10-18 | criteria provided, single submitter | clinical testing | The c.6631A>G (p.I2211V) alteration is located in exon 48 (coding exon 47) of the CDH23 gene. This alteration results from a A to G substitution at nucleotide position 6631, causing the isoleucine (I) at amino acid position 2211 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |